Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis

Z. Diamant, L. Franciosi, N. Morelli, R. Zuiker, I. Kamerling, M. de Kam, K. Burggraaf, A. Cohen, M. Walker, C. Page (Lund, Sweden; Groningen, Leiden, Netherlands; London, United Kingdom; Vancouver, Canada)

Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Session: Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Session type: Thematic Poster Session
Number: 708
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Z. Diamant, L. Franciosi, N. Morelli, R. Zuiker, I. Kamerling, M. de Kam, K. Burggraaf, A. Cohen, M. Walker, C. Page (Lund, Sweden; Groningen, Leiden, Netherlands; London, United Kingdom; Vancouver, Canada). Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis. Eur Respir J 2013; 42: Suppl. 57, 708

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Year: 2013

LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma.
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014

Combined therapy of asthma and allergic rhinitis
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014

Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014


The effect of inhaled ciclesonide on airway blood flow
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Effect of vitamin d therapy on the pulmonary functions in pediatric asthma and allergic rhinitis
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016


Pharmacogenetics in severity of bronchial hyperresponsiveness in asthma
Source: Annual Congress 2013 –Genetic factors in airway development and disease
Year: 2013

Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015

Chronic dosing effects of propranolol in asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Study of some inflammatory markers in children with moderate persistent bronchial asthma before and after therapy with inhaled corticosteroids
Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules
Year: 2013

Montelukast improves air trapping, not airway remodeling, in moderate-to-severe patients with asthma: A pilot tudy
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


The effect of treatment duration by inhaled glucocorticosteroids, on “cough variant asthma” in children
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013

Effect of roflumilast on airway remodeling in a murine model of chronic asthma
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015


HDM sublingual AIT tablet is well-tolerated and effective in partly and uncontrolled allergic asthma
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015


Treatment of asthma the current European perspective
Source: Annual Congress 2006 - Childhood asthma therapy: where we are now and where we need to go
Year: 2006